Alexion Reports Third Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharmaceuticals (ALXN) PT Raised to $122 at Jefferies Following 3Q
October 27, 2017 8:45 AM EDTJefferies raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $122.00 (from $121.00) while maintaining a Hold rating following the company's 3Q. ~In-line Soliris sales of ~$756M offset by lower non-GAAP OpEx and taxes, resulted in higher non-GAAP EPS of $1.44 (vs. consensus of... More
Alexion Pharma (ALXN) Tops Q3 EPS by 12c, Sales Miss; Bumps Outlook
October 26, 2017 6:32 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.44, $0.12 better than the analyst estimate of $1.32. Revenue for the quarter came in at $859 million versus the consensus estimate of $864.45 million.
GUIDANCE:
Alexion Pharma sees FY2017 EPS of $5.50-$5.65, versus prior of $5.40-$5.55... More
